Proposal for an innovating business model for supporting biotechnology companies, ecosystem and their founders

2019 ◽  
Vol 24 (3) ◽  
Author(s):  
Fabrice Heitzmann
Keyword(s):  
Intellectual Property ◽  
Pharmaceutical Industry ◽  
Business Model ◽  
Market Performance ◽  
Market Growth ◽  
Current Economic Climate ◽  
Economic Climate ◽  
Biotechnology Companies ◽  
The Right

The pharmaceutical industry has been revolutionized by the new biotechnology companies during the last years. Facing patent expirations, lack of innovation and depleting product pipelines, the important structures turned to the funding of small biotechnology companies aimed at research and intellectual property securization. Alliances are primordial in the current economic climate. The market growth was questioned for years, but biotechnology companies shifted to product-driven strategies and the market performance has been verified during the last decade. Researchers still face challenges in transforming their science into businesses. They need to be fully equipped, and accompanied towards the right objectives to ensure the sustainability of the market as a whole.

scholarly journals Time for a new business model?

1969 ◽  
Vol 16 (1) ◽  
Author(s):  
Yali Friedman
Keyword(s):  
Business Model ◽  
Hybrid Model ◽  
Business Models ◽  
The United States ◽  
Biotechnology Industry ◽  
New Firms ◽  
Technology Platform ◽  
Economic Climate ◽  
New Business ◽  
Biotechnology Companies

In the relatively short history of the biotechnology industry, new business models have emerged every few years. Some have been little more than short-lived marketing or investment-attraction devices, whereas others have had endured as viable options. Given the dramatic changes in the economic climate and potentially the regulations affecting biotechnology, is it time for a new business model?A SHORT HISTORYFirst there was the FILCO, or fully integrated life science company, business model. This model, employed by some of the first biotechnology companies, positioned firms to capture the revolutionary advances of biotechnology and to build large vertically-integrated companies. Companies like Amgen and Genentech were able to fulfill this endpoint, but many other companies were not so fortunate. Another early model was to improve existing products, rather than to build an entire franchise around discovering and commercializing new ones. This model is exemplified by Alza, which was founded to improve medical treatment through controlled drug delivery and focused on improving existing drugs rather than developing new ones. This same model is still employed today, and shares some similarity with the technology platform business model, where companies focus on developing technologies that can be sold to other R&D firms, rather than independently developing consumer applications.Newer business models did not replace the older ones, but rather enabled new firms to focus on the unique environment in which they were founded. Examples include the hybrid model that combined product development with a technology platform, which could be sold or licensed to others, and the no research, development-only model that as a derivative of the specialty pharmaceutical model, saw newly founded companies buying drug leads off of other companies to complete late-stage clinical trials. These models enabled new firms to meet the respective needs of risk-averse and cash-rich investors.WHERE ARE WE NOW?I've previously written that the global economic crisis has been (and still is) transformative for the biotechnology industry. The aforementioned biotechnology business models rose to prominence in conditions that favored them. For example, the hybrid model emerged in a funding drought and was favored as it enabled companies to build internal revenue streams while still maintaining the possibility to realize the upside of product sales.What are the factors influencing biotechnology companies today? In the United States, beyond the general economic climate there are still unresolved questions about the availability of early stage financing, the ability to recruit foreign workers, and – post-commercialization – data exclusivity, generic biologics and the potential for price controls. Internationally, some nations are still undergoing dramatic economic reorganizations, while others are making significant investments in building biotechnology R&D capacity.So, the question remains: Is the biotechnology industry ready for a new business model, and is there a business model that can accommodate the myriad domestic challenges faced by many countries while addressing the increasing globalization of activities?

scholarly journals CONHECIMENTOS TRADICIONAIS E O DIREITO EMPRESARIAL ÀS PATENTES

Percurso ◽  
2019 ◽  
Vol 4 (31) ◽  
pp. 93
Author(s):  
Ana Carolina Lucena BRITO ◽  
André Luís Fregapani LEITE ◽  
Valmir César POZZETTI
Keyword(s):  
Sustainable Development ◽  
Intellectual Property ◽  
Industrial Property ◽  
Contractual Relationship ◽  
Federal Constitution ◽  
The People ◽  
The World ◽  
Biotechnology Companies ◽  
World Organization ◽  
The Right

RESUMOO objetivo desta pesquisa foi o analisar a relação contratual que se forma entre as empresas de biotecnologia e os povos tradicionais, quando as primeiras utilizam-se dos conhecimentos dos segundos para reduzir custo e tempo gasto com pesquisas, obtendo lucro, sendo a devida remuneração aos povos tradicionais em virtude dos conhecimentos por eles oferecidos. Ressaltou-se a relevância jurídica da proteção do direito da propriedade intelectual e industrial, perpassando por uma análise da evolução histórica dos instrumentos jurídicos no cenário mundial, podendo-se citar a Convenção da União de Paris, em 1883, seguida da criação da Organização Mundial do Comércio através do Acordo de Marrakesh, em 1994, que teve como seu mais importante instrumento o TRIPS. O TRIPS é um marco pelo qual muitos países regularam suas normas internas acerca da propriedade intelectual, incluindo o Brasil que é consignatário no Acordo. Já no Brasil, este âmbito sofreu modificações após a Constituição Federal, de 1988, garantindo como direito fundamental a propriedade intelectual, até se obter a legislação vigente no país acerca do tema, a Lei nº 9.279/96. A lei por fim regulamentou o registro de patentes e as obrigações inerentes, dentre outras disposições. Sobre tais, destacam-se as patentes verdes que visam tutelar conhecimentos de inovação biotecnológica, a fim de propagar o desenvolvimento sustentável na produção industrial. Todavia, verificou-se que no ramo houve graves violações aos direitos dos povos indígenas e tradicionais, no momento que as empresas utilizavam seus conhecimentos milenares e os patenteavam como se donos fossem. Desse modo, após intensos debates e novas concepções, entendeu-se que tais saberes não podem ser objetos de patentes. Ao fim, concluiu-se que o programa “Patente Verde” pode concorrer para grandes avanços tecnológicos e econômicos no Brasil; mas deve sempre respeitar às diretrizes do desenvolvimento sustentável, no qual se encontram direitos sociais e ambientais, garantindo a razoabilidade dos direitos e assegurando a inviolabilidade dos mesmos.PALAVRAS-CHAVES: Patentes; conhecimentos tradicionais; desenvolvimento sustentável. ABSTRACTThe objective of this research is to analyze the contractual relationship that is formed between biotechnology companies and traditional peoples, when the former use the knowledge of the second to reduce cost and time spent with research, obtaining profit, due to the remuneration to the people their knowledge. The legal relevance of the protection of the right to intellectual and industrial property was emphasized, as well as an analysis of the historical evolution of the legal instruments on the world scene, including the Paris Convention of 1883, followed by the creation of the World Organization through the Marrakesh Agreement in 1994, which had as its most important instrument TRIPS. TRIPS is a milestone for many countries to regulate their internal rules on intellectual property, including Brazil that is a signatory to the Agreement. In Brazil, this scope was modified after the Federal Constitution of 1988, to guarantee as fundamental right the intellectual property, until obtaining the legislation in force in the country on the subject, Law 9.279 / 96. The law finally regulated the registration of patents and the inherent obligations, among other provisions. These include green patents aimed at protecting knowledge of biotechnological innovation in order to promote sustainable development in industrial production. However, it was found that there were serious violations of the rights of indigenous and traditional peoples, as companies used their millennial knowledge and patented them as owners. Thus, after intense debates and new conceptions, it was understood that such knowledge can not be objects of patents. Finally, it was concluded that the green patent program can contribute to major technological and economic advances in Brazil, but should always respect the guidelines of sustainable development, which include social and environmental rights, guaranteeing the reasonableness of rights and ensuring the their inviolability.KEYWORDS: Patents; traditional knowledge; sustainable development. 

scholarly journals Patents and licensing in pharmaceutical industry

2015 ◽  
Vol 61 (01) ◽  
pp. 51-59
Author(s):  
Katerina Ancevska Netkovska ◽  
Jasmina Tonic Ribarska ◽  
Aleksandra Grozdanova ◽  
Zoran Sterjev
Keyword(s):  
Intellectual Property ◽  
Pharmaceutical Industry ◽  
Property Rights ◽  
Management Style ◽  
Industrial Property ◽  
Know How ◽  
Patent License ◽  
License Agreements ◽  
The Status ◽  
The Right

Intellectual property rights (IPR) have been defined as ideas, inventions, and creative expressions based on which there is a public willingness to bestow the status of property. IPR provide certain exclusive rights to the inventors or creators of that property, in order to enable them to reap commercial benefits from their creative efforts or reputation. There are several types of intellectual property protection like patent, copyright, trademark, etc. Patent is recognition for an invention, which satisfies the criteria of global novelty, non-obviousness, and industrial application. IPR is prerequisite for better identification, planning, commercialization, rendering, and thereby protection of invention or creativity. Each industry should evolve its own IPR policies, management style, strategies, and so on depending on its area of specialty. Pharmaceutical industry currently has an evolving IPR strategy requiring a better focus and approach in the coming era. The protection of inventions with patents in the pharmaceutical industry have a specific role in the development of society and represent one of the drivers of economic development. The license agreements are considered as one of the most common types of transfer of industrial property rights. The right holders often transfer their rights to patents by concluding licensing agreement. While the patent license may give the license a right to use the technology many license agreements have provisions for the transfer of know-how in addition to the patent.

The Code Breaker: Jennifer Doudna, gene editing, and the future of the human race

2021 ◽  
Vol 26 (2) ◽  
Author(s):  
Arthur A Boni
Keyword(s):  
Technology Transfer ◽  
Business Model ◽  
High Performance ◽  
Gene Editing ◽  
Team Building ◽  
Human Race ◽  
Academic Scientist ◽  
Biotechnology Companies ◽  
Academic Laboratory

In this book review and accompanying commentary and Addendum, we focus on 5 principal topics/major themes that are of interest for our readership, with a focus on framing the translation of transformative technology into a platform business model in biopharma.  We focus on: 1) the behavioral and personal side of the story of the academic scientist, in this case the principal “code breaker” – Jennifer Doudna; 2) the innovation/technology transfer models, including team building appropriate for successfully translating technology from the academic laboratory into the private sector; 3) the IP considerations needed for broad commercialization and dissemination of pivotal, platform inventions in biopharma; and, 4) framing the issues surrounding the ethical discussion related to use in patients associated with a transformative, gene based technology like CRISPR. We also include an Addendum that covers, 5) Some pertinent, concluding comments on the importance of high–performance, diverse teams for founding, building, and growing successful biotechnology companies.

scholarly journals Governing Knowledge: Intellectual Property Management for Development and the Public Interest

2015 ◽  
Vol 66 ◽  
pp. 69-88
Author(s):  
Leonardo Burlamaqui
Keyword(s):  
Intellectual Property ◽  
Public Interest ◽  
Public Domain ◽  
Policy Recommendations ◽  
Public And Private ◽  
The Public ◽  
Private Interests ◽  
Intellectual Property Management ◽  
Analytical Perspective ◽  
The Right

The core point of this paper is the hypothesis that in the field of intellectual property rights and regulations, the last three decades witnessed a big change. The boundaries of private (or corporate) interests have been hyper-expanded while the public domain has significantly contracted. It tries to show that this is detrimental to innovation diffusion and productivity growth. The paper develops the argument theoretically, fleshes it out with some empirical evidence and provides a few policy recommendations on how to redesign the frontiers between public and private spaces in order to produce a more democratic and development-oriented institutional landscape. The proposed analytical perspective developed here, “Knowledge Governance”, aims to provide a framework within which, in the field of knowledge creation and diffusion, the dividing line between private interests and the public domain ought to be redrawn. The paper’s key goal is to provide reasoning for a set of rules, regulatory redesign and institutional coordination that would favor the commitment to distribute (disseminate) over the right to exclude.Keywords: knowledge management, intellectual property, patent, public, interest, public sector, private sector, socioeconomic developmen

scholarly journals KEEPING THE NATION'S ASSETS THROUGH THE LEGAL PROTECTION OF COPYRIGHT WORKS OF CULTURE

2016 ◽  
Vol 1 (1) ◽  
pp. 55-71
Author(s):  
Zulkifli Makkawaru
Keyword(s):  
Intellectual Property ◽  
Property Rights ◽  
Intellectual Property Rights ◽  
Legal Protection ◽  
Literature And Science ◽  
Community Rights ◽  
Art And Culture ◽  
The Right

Indonesia positioned copyright art and culture based on its strength as a nation or community rights over an Alliance grouping of the society which can give the effect of distortions in its protection. Which institution can be megurus and oversee the interests between countriesCultivate ideas/ideas in the fields of art, literature and science in the context of intellectual property rights (HKI) categorized into areas of HKI named Copyright (Copyright). The scope of the rights provided for the protection of copyright in the context of this very broad following elements known in several countries. There is a different understanding about the copyright status of culture from both the substance of the right nor of the appreciation of the case which threatens foreign claims copyright over the culture of Indonesia

Sign in / Sign up

Export Citation Format

Share Document